Clinical Trials Browser

Advanced and Metastatic Urothelial Cancer × futibatinib × 90 days × Clear all

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Advanced and Metastatic Urothelial Cancer